Takeda Pharmaceutical (TAK) Common Equity (2017 - 2026)

Takeda Pharmaceutical's Common Equity history runs 10 years deep, the most recent figure standing at $47.4 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 4.24% year-over-year to $47.4 billion in Q1 2026; TTM through Mar 2026 was $47.4 billion, a 4.24% increase from a year earlier, with the FY2026 full-year figure at $49.4 billion, up 8.42% from the prior year.
• Common Equity slipped to $47.4 billion in Q1 2026 per TAK's latest filing, from $49.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $50.5 billion in Q2 2023 and bottomed at $43.7 billion in Q4 2022.
• The 5-year median for Common Equity is $48.7 billion (2022), against an average of $48.1 billion.
• Across the five-year window, Common Equity increased 6.99% in 2024 and declined 7.39% in 2025, its largest moves.
• Year by year, Common Equity stood at $43.7 billion in 2022, then climbed by 4.34% to $45.6 billion in 2023, then gained by 6.99% to $48.8 billion in 2024, then gained by 1.78% to $49.7 billion in 2025, then fell by 4.61% to $47.4 billion in 2026.
• Per Business Quant, the three latest TAK Common Equity figures stand at $47.4 billion (Q1 2026), $49.7 billion (Q4 2025), and $48.4 billion (Q3 2025).